A Phase 4, Open-Label Study to Evaluate Primary Adrenal Function (Glucocorticoid Axis) in Hypogonadal Men Treated With JATENZO® for 12 Months
Latest Information Update: 24 Oct 2024
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism
- Focus Therapeutic Use
- Acronyms TOL-CLAR-20024
- Sponsors Tolmar
Most Recent Events
- 22 Oct 2024 Status changed from recruiting to active, no longer recruiting.
- 13 May 2024 Status changed from not yet recruiting to recruiting.
- 30 Apr 2024 New trial record